Mostrando 10 resultados de: 151
Filtros aplicados
Publisher
Pharmacogenomics(22)
Pharmacogenomics Journal(17)
Drug Metabolism and Drug Interactions(11)
Drug Metabolism and Personalized Therapy(8)
European Journal of Clinical Pharmacology(8)
Área temáticas
Enfermedades(62)
Bioquímica(34)
Medicina y salud(30)
Fisiología humana(23)
Problemas sociales y servicios a grupos(13)
Challenges and Opportunities for Clinical Pharmacogenetic Research Studies in Resource-limited Settings: Conclusions From the Council for International Organizations of Medical Sciences–Ibero-American Network of Pharmacogenetics and Pharmacogenomics Meeting
ArticleAbstract: Purpose: The symposium Health and Medicines in Indigenous Populations of America was organized by thPalabras claves:CIOMS-RIBEF, clinical research, pharmacogenetics, resource-limited settingsAutores:Adrián LLerena, Diwakar S., Enrique Terán, Galaviz-Hernandez C., Gil J.P., Isabel Hernández, Lara-Riegos J., Molina-Guarneros J.A., Moya G.E., Nair S., Penãs-Lledó E.M., Rägo L., Ramírez-Roa R., Sosa-Macías M.G., Tarazona-Santos E.M., Verde I.Fuentes:googlescopusCharacterization of CYP2D6 genotypes and metabolic profiles in the Portuguese population: Pharmacogenetic implications
ArticleAbstract: CYP2D6 codes for a protein that is vastly involved in the metabolism of various substances. This genPalabras claves:CYP2D6, CYP450, Metabolic profile, pharmacogenetics, Pharmacogenomics, polymorphism, Portuguese populationAutores:Adrián LLerena, Albuquerque J., Grazina M., Naranjo M.E.G., Ribeiro C.Fuentes:scopusClinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update
ReviewAbstract: Phenytoin is an antiepileptic drug with a narrow therapeutic index and large interpatient pharmacokiPalabras claves:Autores:Adrián LLerena, Callaghan J.T., Caudle K.E., Fohner A.E., Formea C.M., Gaedigk A., Huddart R., Karnes J.H., Klein T.E., Mintzer S., Phillips E.J., Rettie A.E., Somogyi A.A., Ta Michael Lee M., Whirl-Carrillo M.Fuentes:scopusClinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors
ArticleAbstract: Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive aPalabras claves:Autores:Adrián LLerena, Bishop J.R., Caudle K.E., Chiulli D.L., Gaedigk A., Graham R.L., Hicks J.K., Ji Y., Klein T.E., Leckband S.G., Leeder J.S., Muller D.J., Sangkuhl K., Scott S.A., Skaar T.C., Stingl J.C.Fuentes:scopusClinical drug-drug interactions: Focus on venlafaxine
ReviewAbstract: Venlafaxine (VEN) is an antidepressant agent widely used nowadays as an alternative to selective serPalabras claves:Drug-drug interactions, pharmacodynamics, pharmacokinetics, VenlafaxineAutores:Adrián LLerena, Alves G., Falcao A.C., Magalhães P.Fuentes:scopusClinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs
ReviewAbstract: CYP2D6 is described as the most relevant enzyme in the metabolism of many antipsychotic drugs. Its cPalabras claves:Antipsychotic drugs, CYP2D6, pharmacogenetics, PharmacogenomicsAutores:Adrián LLerena, Berecz R., Cáceres M.C., Dorado P., Penãs-Lledó E.M.Fuentes:scopusClinical pharmacology of drug metabolism and drug interactions: Clinical, interethnical and regulatory aspects
OtherAbstract:Palabras claves:Autores:Adrián LLerenaFuentes:scopusClinical use of pre-emptive pharmacogenetic programmes
OtherAbstract:Palabras claves:Autores:Adrián LLerena, Penãs-Lledó E.M.Fuentes:scopusClozapine disposition covaries with CYP1A2 activity determined by a caffeine test.
ArticleAbstract: In a previous study we showed that the disposition of clozapine after a single oral dose is unrelatePalabras claves:Autores:Adrián LLerena, Alm C., Benitez Rodriguez J., Bertilsson L., Bondesson U., Carrillo J., Dahl M.L., Lindstrom L., Ramos S., Rodriguez de la Rubia I.Fuentes:scopusClozapine withdrawal symptoms after change to sertindole in a schizophrenic patient
ArticleAbstract: A 30-year-old male patient with paranoid schizophrenia was on clozapine therapy for more than five yPalabras claves:Autores:Adrián LLerena, Berecz R., De la Rubia A., Degrell I., Glaub T., Kellermann M.Fuentes:scopus